

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
 and searchable
 NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
 CA/Caplus
 NEWS 5 FEB 05 German (DE) application and patent publication number format
 changes
 NEWS 6 MAR 03 MEDLINE and LMedLINE reloaded
 NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
 NEWS 8 MAR 03 FRANCEPAT now available on STN
 NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
 NEWS 10 MAR 29 WPIFV now available on STN
 NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12 APR 26 PROMT: New display field available
 NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
 available
 NEWS 14 APR 26 LITAlert now available on STN
 NEWS 15 APR 27 NLDB: New search and display fields available
 NEWS 16 May 10 PROUSDDR now available on STN
 NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
 and June 2004
 NEWS 18 May 12 EXTEND option available in structure searching
 NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20 May 17 FRFULL now available on STN
 NEWS 21 May 27 STN User Update to be held June 7 and June 8 at the SLA 2004
 Conference
 NEWS 22 May 27 New UPM (Update Code Maximum) field for more efficient patent
 SDIs in Caplus
 NEWS 23 May 27 Caplus super roles and document types searchable in REGISTRY
 NEWS 24 May 27 Explore APOLLIT with free connect time in June 2004
 NEWS EXPRESS. MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
 MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUN 2004 HIGHEST RN 690955-30-7
 DICTIONARY FILE UPDATES: 8 JUN 2004 HIGHEST RN 690955-30-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> file bradykinin () ?agonist?

'BRADYKININ' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
 that are available. If you have requested multiple files, you can
 specify a corrected file name or you can enter "IGNORE" to continue
 accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.63

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 9 Jun 2004 VOL 140 ISS 24
 FILE LAST UPDATED: 8 Jun 2004 (20040608/ED)

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

```
=> s bradykinin () ?agonist?
      16404 BRADYKININ
      191 BRADYKININS
      16431 BRADYKININ
          (BRADYKININ OR BRADYKININS)
      281357 ?AGONIST?
L1      671 BRADYKININ (W) ?AGONIST?

=> s l1 and vascu?
      135827 VASCU?
L2      58 L1 AND VASCU?

=> s l2 and diabet?
      101185 DIABET?
L3      1 L2 AND DIABET?

=> s l3 and review/dt
      1732992 REVIEW/DT
L4      0 L3 AND REVIEW/DT

=> s l2 and review/dt
      1732992 REVIEW/DT
L5      4 L2 AND REVIEW/DT

=> d l5, ibib abs, 1-4

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
```

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	2002:895266 HCAPLUS
DOCUMENT NUMBER:	138:395181
TITLE:	Bradykinin antagonists as new drugs for prostate cancer
AUTHOR(S):	Stewart, John M.; Chan, Daniel C.; Simkeviciene, Vitalija; Bunn, Paul A.; Helfrich, Barbara; York, Eunice J.; Taraseviciene-Stewart, Laimute; Bironaite, Daiva; Gera, Lajos
CORPORATE SOURCE:	Department of Biochemistry, University of Colorado School of Medicine, Denver, CO, 80262, USA
SOURCE:	International Immunopharmacology (2002), 2(13-14), 1781-1786 CODEN: IINMBA; ISSN: 1567-5769
PUBLISHER:	Elsevier Science B.V.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English
AB	A review. Bradykinin (BK) is an autocrine growth factor for lung and prostate cancers. BK also facilitates tumor extension by increasing tissue permeability and stimulating angiogenesis. Peptide BK antagonists are in development as potential new drugs for lung cancer. Newer nonpeptide BK antagonists have even higher potency against lung cancer, in vitro and in vivo. These compds. have now been applied to the study of prostate cancers, and have been effective. Prostate cancer cell line PC3 is derived from a late-stage, hormone-independent, metastatic tumor; its growth is difficult to inhibit. Our established BK antagonists, while less effective against this line of prostate cancer in xenografts in nude mice than against lung cancer, are active and have led the way to development of new peptide and nonpeptide agents for prostate cancer. In addn. to inhibiting cancer cell growth directly, they inhibit angiogenesis mediated by vascular endothelial growth factor, and inhibit increased tissue permeability mediated by membrane metalloproteases in these tumors.

This class of compds. offers hope for development of new drugs for refractory prostate cancer.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 2000:324230 HCAPLUS
DOCUMENT NUMBER: 133:83738
TITLE: Kallikrein-kinin system in acute pancreatitis: potential of B2-bradykinin antagonists and kallikrein inhibitors
AUTHOR(S): Griesbacher, Thomas
CORPORATE SOURCE: Department of Experimental and Clinical Pharmacology, University of Graz, Graz, A-8010, Austria
SOURCE: Pharmacology (2000), 60(3), 113-120
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: S. Karger AG
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 36 refs. The development of selective antagonists for bradykinin B2 receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the **vascular** symptoms, i.e. pancreatic edema formation and its consequences, such as hemoconcn., hypovolemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B2 antagonists must begin prior to the formation of pancreatic edema to inhibit or attenuate the **vascular** effects. Visceral pain as a possible target symptom for treatment with B2 antagonists at later time points is suggested by the B2 receptor-mediated activation of nociceptive afferents.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing References

ACCESSION NUMBER: 1993:401036 HCAPLUS
DOCUMENT NUMBER: 119:1036
TITLE: Therapeutic prospects of bradykinin receptor antagonists
AUTHOR(S): Sharma, J. N.
CORPORATE SOURCE: Sch. Med. Sci., Univ. Sains Malaysia, Kubang Kerian, 16150, Malay.
SOURCE: General Pharmacology (1993), 24(2), 267-74
CODEN: GEPHDP; ISSN: 0306-3623
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 77 refs. Bradykinin (BK) and related kinins may act on 4 types of receptors designated as B1, B2, B3, and B4. It seems that the B2 receptors are most commonly found in various **vascular** and non-**vascular** smooth muscles, whereas B1 receptors are formed in vitro during trauma, and injury, and are found in bone tissues. These BK receptors are involved in the regulations of various physiol. and pathol. processes. The mode of kinin actions are based upon the interactions between the kinin and their specific receptors, which can led to activation of several second-messenger systems. Numerous BK receptor antagonists have been synthesized with prime aim to treat diseases caused by excessive kinin

prodn. These diseases are RA, inflammatory diseases of the bowel, asthma, rhinitis and sore throat, allergic reactions, pain, inflammatory skin disorders, endotoxin and anaphylactic shock and coronary heart diseases. On the other hand, BK receptor antagonists could be contraindicated in hypertension, since these drugs may antagonize the antihypertensive therapy and/or may trigger the hypertensive crisis. It is worth suggesting that the BK receptor agonists might be useful antihypertensive drugs.

L5 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1968:28157 HCAPLUS
 DOCUMENT NUMBER: 68:28157
 TITLE: **Bradykinin antagonists** and mediation of **vascular** phenomena of acute inflammation
 AUTHOR(S): Rocha e Silva, Mauricio
 CORPORATE SOURCE: Dep. Pharmacol., Fac. Med., Univ. Sao Paulo, Sao Paulo, Brazil
 SOURCE: Actualites de Physiologie Pathologique (1966), 1, 23-45
 CODEN: APPABD; ISSN: 0567-8714
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB A discussion and review with 88 references.

=> d his

(FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004

L1 671 S BRADYKININ () ?AGONIST?
 L2 58 S L1 AND VASCU?
 L3 1 S L2 AND DIABET?
 L4 0 S L3 AND REVIEW/DT
 L5 4 S L2 AND REVIEW/DT

=> s l1 and diab?

112055 DIAB?

L6 9 L1 AND DIAB?

=> s l6 and review/dt

1732992 REVIEW/DT

L7 1 L6 AND REVIEW/DT

=> d 17, ibib abs, 1

L7 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:263168 HCAPLUS
 DOCUMENT NUMBER: 132:317521
 TITLE: Organic chemistry 1999. Medicinal chemistry
 AUTHOR(S): Garcia-Echeverria, Carlos; Maibaum, Jurgen; Metternich, Rainer; Pombo-Villar, Esteban; Sedrani, Richard; Veenstra, Siem
 CORPORATE SOURCE: Novartis Pharma AG, Basel, Switz.

SOURCE: Nachrichten aus der Chemie (2000), 48(3), 284-290
 CODEN: NACHFB; ISSN: 1439-9598
 PUBLISHER: Wiley-VCH Verlag GmbH
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: German
 AB A review with 80 refs. is given on the following fields of research in medicinal chem. in 1999: protein kinase inhibitors, immunosuppressive substances in transplantation, adiposity and **diabetes**, non-substrate binding sites of proteases, **bradykinin antagonists**, neurokinins, and corticotropin-releasing factor (CRF) antagonists.
 REFERENCE COUNT: 111 THERE ARE 111 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

=> d his

(FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004

L1 671 S BRADYKININ () ?AGONIST?
 L2 58 S L1 AND VASCU?
 L3 1 S L2 AND DIABET?
 L4 0 S L3 AND REVIEW/DT
 L5 4 S L2 AND REVIEW/DT
 L6 9 S L1 AND DIAB?
 L7 1 S L6 AND REVIEW/DT

=> s l1 and psori?

10739 PSORI?

L8 4 L1 AND PSORI?

=> s l8 and review/dt

1732992 REVIEW/DT

L9 0 L8 AND REVIEW/DT

=> s bradykinin () ?inhib?

16404 BRADYKININ

191 BRADYKININS

16431 BRADYKININ

(BRADYKININ OR BRADYKININS)

1666481 ?INHIB?

L10 319 BRADYKININ (W) ?INHIB?

=> s l10 and review/dt

1732992 REVIEW/DT

L11 12 L10 AND REVIEW/DT

=> d l11, ibib abs, 1-12

L11 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text **Citing References**

ACCESSION NUMBER: 2003:836065 HCAPLUS

DOCUMENT NUMBER: 140:245723

TITLE: Bradykinin-1 receptor antagonists

AUTHOR(S): Bock, Mark G.; Hess, J. Fred; Pettibone, Douglas J.

CORPORATE SOURCE: Merck Research Laboratories, West Point, PA, 19486,

USA
 SOURCE: Annual Reports in Medicinal Chemistry (2003), 38,
 111-120
 CODEN: ARMCB; ISSN: 0065-7743
 PUBLISHER: Elsevier Science
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English
 AB A review on recent developments in understanding of an active bradykinin
 B1 receptor mechanism in the central nervous system which has broadened
 the analgesic potential of blocking this receptor. B1 antagonists exhibit
 an analgesic profile that overlaps significantly with the opiates, but are
 unlikely to exhibit the unwanted side effects of morphine-like drugs.
 Targeting both peripheral and central sites of action could be important
 for optimizing the efficacy of this novel class of compds.
 REFERENCE COUNT: 86 THERE ARE 86 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2001:824360 HCAPLUS
DOCUMENT NUMBER:	136:177309
TITLE:	Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
AUTHOR(S):	Andersen, Niels Holmark; Mogensen, Carl Erik
CORPORATE SOURCE:	Department of Internal Medicine, M Kommunehospital University Hospital, DK-Aarhus C, DK-8000, Den.
SOURCE:	JRAAS (2001), 2(3), 146-152 CODEN: JRAAAG; ISSN: 1470-3203
PUBLISHER:	JRAAS Ltd.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English
AB	A review summarizes the latest trials concerning attenuation of the renin-angiotensin system (RAS), highlighting the use of dual blockade treatment. Modulation of RAS has become essential in treating hypertension and delaying the onset of diabetic nephropathy. The use of angiotensin-converting enzyme inhibitors (ACE-I) has beneficial effects when treating hypertension and renal disease in diabetes, as well as non-diabetic renal disease. By dual blockade treatment (combining an ACE-I and an angiotensin AT1-receptor blocker), it might be possible to obtain a more complete inhibition of the RAS and thus greatly enhance the desired therapeutic effect. Dual blockade might also be able to block the effects of both non-ACE pathways and tissue-ACE activity, since both ACE and the AT1-receptor are inhibited simultaneously, thereby increasing bradykinin levels.
REFERENCE COUNT:	56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
ACCESSION NUMBER:	2000:324230 HCAPLUS
DOCUMENT NUMBER:	133:83738
TITLE:	Kallikrein-kinin system in acute pancreatitis: potential of B2-bradykinin antagonists and kallikrein inhibitors
AUTHOR(S):	Griesbacher, Thomas
CORPORATE SOURCE:	Department of Experimental and Clinical Pharmacology, University of Graz, Graz, A-8010, Austria
SOURCE:	Pharmacology (2000), 60(3), 113-120

CODEN: PHMGBN; ISSN: 0031-7012

PUBLISHER:

S. Karger AG

DOCUMENT TYPE:

Journal; **General Review**

LANGUAGE:

English

AB A review with 36 refs. The development of selective antagonists for bradykinin B2 receptors has greatly advanced research on the role of the kallikrein-kinin system in acute pancreatitis. Kinins released during the course of the inflammatory injury are the major cause of the vascular symptoms, i.e. pancreatic edema formation and its consequences, such as hemoconcn., hypovolemia and hypotension. Kinins are also involved in the accumulation of potentially cytotoxic factors in the pancreatic tissue. However, treatment with B2 antagonists must begin prior to the formation of pancreatic edema to inhibit or attenuate the vascular effects. Visceral pain as a possible target symptom for treatment with B2 antagonists at later time points is suggested by the B2 receptor-mediated activation of nociceptive afferents.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN



ACCESSION NUMBER: 2000:264440 HCAPLUS

DOCUMENT NUMBER: 133:26382

TITLE: A novel class of highly potent and orally active nonpeptide bradykinin B2 receptor antagonists

AUTHOR(S): Sawada, Yuki; Kayakiri, Hiroshi; Abe, Yoshito; Satoh, Shigeki; Inoue, Takayuki; Oku, Teruo; Tanaka, Hirokazu

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Ibaraki, 300-2698, Japan

SOURCE: Peptide Science (1999), 36th, 41-44

CODEN: PSCIFQ; ISSN: 1344-7661

PUBLISHER: Japanese Peptide Society

DOCUMENT TYPE: Journal; **General Review**

LANGUAGE: English

AB A review, with 5 refs. describing the authors' work. Highly potent, selective and orally active non-peptide bradykinin B2 receptor antagonists have been discovered. A lead compd. was found by a two-step directed random screening process. Extensive chem. modification of the lead compd. revealed the structure-activity relationships (SAR) and led to discovery of a clin. candidate, FK3657. The active conformation suggested by a mol. modeling study was chem. proved. Further optimization afforded pyrrole derivs. which bind to recombinant human B2 receptors more potently than a second generation peptide B2 antagonist, Icatibant.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN



ACCESSION NUMBER: 1997:83423 HCAPLUS

DOCUMENT NUMBER: 126:126991

TITLE: Angiotensin II receptors and renal hemodynamics and function

AUTHOR(S): Ichikawa, Iekuni

CORPORATE SOURCE: Division of Pediatric Nephrology, Vanderbilt University School of Medicine, Nashville, TN, USA

SOURCE: Blood Pressure, Supplement (1996), (2, Angiotensin II Receptors), 19-21

CODEN: BPSUEY; ISSN: 0803-8023

PUBLISHER: Scandinavian University Press
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English

AB A review, with 7 refs. The biol. action of angiotensin-converting enzyme (ACE) includes conversion of angiotensin I to angiotensin II (A II) and degrdn. of bradykinin. Thus, pharmacol. blockade of ACE is expected to augment endogenous bradykinin activity. A study using a specific **bradykinin inhibitor** revealed that the activation of bradykinin by an ACE inhibitor has the potential to affect the function of the kidney in several ways. It has been shown in vitro that bradykinin is a highly selective efferent (vs. afferent) arteriolar dilator. An in vivo study using both ACE inhibitors and bradykinin antagonists demonstrated that, through this efferent-arteriolar dilating effect, the bradykinin activated by ACE inhibition causes a profound redn. in glomerular pressure. In contrast, the latter phenomenon is absent during administration of an angiotensin II type 1 (AT1)-receptor antagonist, a finding consistent with the notion that AT1 antagonists are devoid of kininase inhibitory action. Due to this difference, AT1 antagonists appear to be inherently better A II inhibitors than ACE inhibitors where glomerular filtration is concerned. This speculation was verified in an acute exptl. setting. It is conceivable, however, that the relatively high glomerular pressure maintained during AT1-antagonist administration may have different effects on the kidney in the long term, because the salutary effect of ACE inhibition to protect kidneys from progressive damage in chronic renal disease is attributed in part to its potent glomerular-pressure-lowering effect. The long-term effects of losartan in the kidney will need to be examd. in human studies.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1995:198456 HCAPLUS
 DOCUMENT NUMBER: 122:1116
 TITLE: Bradykinin agonists and antagonists with replacement of proline in position 7 by nonproteinogenic D-amino acids
 AUTHOR(S): Reissmann, S.; Greiner, G.; Schwuchow, C.; Pineda, L.F.; Liebmann, C.; Paegelow, I.; Wiesmuller, K.-H.; Stewart, J. M.
 CORPORATE SOURCE: Institute of Biochemistry and Biophysics, Friedrich-Schiller-University, Jena, O-6900, Germany
 SOURCE: Chemistry of Peptides and Proteins (1993), 5/6(Pt. A), 377-88
 CODEN: CHPPER; ISSN: 0723-6271
 PUBLISHER: Verlag Mainz, Wissenschaftsverlag
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English

AB A review, with 10 refs., on the effects of substitutions in positions seven (and eight) of bradykinin by phenylalanine analogs, C α -substituted amino acids, and C β -substituted amino acids on their agonist and antagonist properties in different biol. systems.

L11 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1994:692888 HCAPLUS
 DOCUMENT NUMBER: 121:292888
 TITLE: new and highly potent bradykinin antagonists

AUTHOR(S): Knolle, J.; Breipohl, G.; Henke, S.; Wirth, K.; Schoelkens, B.
 CORPORATE SOURCE: HOECHST AG, Frankfurt/Main, D-6230, Germany
 SOURCE: Chemistry of Peptides and Proteins (1993), 5/6(Pt. A), 389-95
 CODEN: CHPPER; ISSN: 0723-6271
 PUBLISHER: Verlag Mainz, Wissenschaftsverlag
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English
 AB A review, with 13 refs., on bradykinin-antagonizing and bradykinin receptor-binding activities achieved by substitutions on bradykinin using isolated guinea pig pulmonary arteries contracted with bradykinin (IC50) and guinea pig ileum with radiolabeled bradykinin (Ki). HOE 140 was chosen for more intensive investigation.

L11 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1990:526633 HCAPLUS
 DOCUMENT NUMBER: 113:126633
 TITLE: Development of competitive antagonists of bradykinin
 AUTHOR(S): Stewart, John M.; Vavrek, Raymond J.
 CORPORATE SOURCE: Sch. Med., Univ. Colorado, Denver, CO, 80262, USA
 SOURCE: Advances in Experimental Medicine and Biology (1989), 247A(Kinins 5, Pt. A), 81-6
 CODEN: AEMBAP; ISSN: 0065-2598
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English
 AB A review, with 13 refs., on the discovery, characterization, and application of synthetic peptides that are specific and competitive antagonists of bradykinin.

L11 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1990:471377 HCAPLUS
 DOCUMENT NUMBER: 113:71377
 TITLE: Kinin antagonists: design and activities
 AUTHOR(S): Stewart, John M.; Vavrek, Raymond J.
 CORPORATE SOURCE: Sch. Med., Univ. Colorado, Denver, CO, 80262, USA
 SOURCE: Journal of Cardiovascular Pharmacology (1990), 15(Suppl. 6), S69-S74
 CODEN: JCPCDT; ISSN: 0160-2446
 DOCUMENT TYPE: Journal; **General Review**
 LANGUAGE: English
 AB A review, with 18 refs., on bradykinin analogs which act as kinin antagonists and on structural requirements conferring antagonist activity, tissue specificity, and enzyme resistance.

L11 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

ACCESSION NUMBER: 1987:44015 HCAPLUS
 DOCUMENT NUMBER: 106:44015
 TITLE: Bradykinin competitive antagonists: design and applications
 AUTHOR(S): Stewart, J. M.; Vavrek, R. J.
 CORPORATE SOURCE: Med. Sch., Univ. Colorado, Denver, CO, 80262, USA
 SOURCE: Protides of the Biological Fluids (1986), 34, 473-6
 CODEN: PBFPA6; ISSN: 0079-7065

DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 11 refs., of structure-activity relations of bradykinin [58-82-2] antagonists.

L11 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing
 Text References

ACCESSION NUMBER: 1978:484899 HCAPLUS
 DOCUMENT NUMBER: 89:84899
 TITLE: Modifiers of the response to kinins and their interactions with other systems
 AUTHOR(S): Stewart, John M.
 CORPORATE SOURCE: Dep. Biochem., Univ. Colorado Sch. Med., Denver, CO, USA
 SOURCE: DHEW Publ. (NIH) (U. S.) (1976), Volume Date 1974, NIH-76-791, Chem. Biol. Kallikrein-Kinin Syst. Health Dis., 287-94
 CODEN: DHEPDG
 DOCUMENT TYPE: Report; General Review
 LANGUAGE: English
 AB A review with 42 refs. on bradykinin [58-82-2] inhibitors and esp. kinin potentiators.

L11 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Text Citing
 Text References

ACCESSION NUMBER: 1974:92782 HCAPLUS
 DOCUMENT NUMBER: 80:92782
 TITLE: Gel filtration
 AUTHOR(S): Moriya, Hiroshi
 CORPORATE SOURCE: Fac. Pharm., Sci. Univ. Tokyo, Tokyo, Japan
 SOURCE: Seibutsu Butsuri Kagaku (1973), 17(3), 155-61
 CODEN: SBBKA4; ISSN: 0031-9082
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: Japanese
 AB Gel filtration is reviewed with 5 examples. They are the purifn. of human pancreatic kallikrein after (NH₄)₂SO₄ fractionation, the estn. of mol. wt. of potato kallikrein inhibitors and bradykinin-inactivating enzyme from potatoes, the application of human serum profile to clin. diagnosis, the change of eluent vol. of buffer in enzymes with and without substrate, and the denaturation of RNase by urea.

=> s bradykinin () eczem?
 16404 BRADYKININ
 191 BRADYKININS
 16431 BRADYKININ
 (BRADYKININ OR BRADYKININS)
 3535 ECZEM?

L12 0 BRADYKININ (W) ECZEM?

=> d his

(FILE 'HOME' ENTERED AT 23:03:30 ON 09 JUN 2004)

FILE 'REGISTRY' ENTERED AT 23:03:36 ON 09 JUN 2004

FILE 'HCAPLUS' ENTERED AT 23:04:24 ON 09 JUN 2004

L1 671 S BRADYKININ () ?AGONIST?

L2 58 S L1 AND VASCU?
 L3 1 S L2 AND DIABET?
 L4 0 S L3 AND REVIEW/DT
 L5 4 S L2 AND REVIEW/DT
 L6 9 S L1 AND DIAB?
 L7 1 S L6 AND REVIEW/DT
 L8 4 S L1 AND PSORI?
 L9 0 S L8 AND REVIEW/DT
 L10 319 S BRADYKININ () ?INHIB?
 L11 12 S L10 AND REVIEW/DT
 L12 0 S BRADYKININ () ECZEM?

=> s l1 and eczem?

3535 ECZEM?

L13 1 L1 AND ECZEM?

=> s l13 and review/dt

1732992 REVIEW/DT

L14 0 L13 AND REVIEW/DT

=> s l1 and spasm?

13409 SPASM?

L15 8 L1 AND SPASM?

=> s l15 and review/dt

1732992 REVIEW/DT

L16 0 L15 AND REVIEW/DT

=> s l1 and chrohn?

7 CHROHN?

L17 0 L1 AND CHROHN?

=> s l1 and ulcer?

32459 ULCER?

L18 3 L1 AND ULCER?

=> s l18 and review/dt

1732992 REVIEW/DT

L19 0 L18 AND REVIEW/DT

=> s l18 and pancr?

107327 PANCR?

L20 1 L18 AND PANCR?

=> s l20 and review/dt

1732992 REVIEW/DT

L21 0 L20 AND REVIEW/DT

=>